Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ebrotidine (FI3542) 是有效的、竞争性的H2受体的拮抗剂,Ki 为127.5nM。Ebrotidine 具有抗分泌活性,可用于胃保护。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 245 | 现货 | ||
5 mg | ¥ 587 | 现货 | ||
10 mg | ¥ 915 | 现货 | ||
25 mg | ¥ 1,550 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 646 | 现货 |
产品描述 | Ebrotidine (FI3542) is a competitive H2-receptor antagonist with Ki of 127.5 nM. Ebrotidine has a potent antisecretory activity and evidenced gastroprotection. |
靶点活性 | H2 receptor:127.5 nM(Ki) |
体外活性 | Ebrotidine displaced 3H-thiotidine specific binding to histamine H2-receptors (Ki: 127.5 nmol/l), showing a higher affinity (p < 0.05) than ranitidine (Ki: 190.0 nmol/l) and cimetidine (Ki: 246.1 nmol/l) [1]. |
体内活性 | Ebrotidine inhibited histamine- and pentagastrin-stimulated acid secretion in a dose-dependent manner (ED50: 0.21 and 0.44 mg/kg, respectively), following intravenous administration to rats [2]. Results of the macroscopic assessment revealed that ebrotidine at doses of 50mg and higher/kg body weight effectively prevented mucosal injury and that the maximal protective effect was achieved by 1h. Physicochemical analysis established that ebrotidine evoked 30% increase in mucus gel dimension, and showed a 20% increase in phospholipids, and the content of sulfo- (18%) and sialomucins (21%) [4]. The mean number of gastric erosions seen at endoscopy after treatment with ebrotidine plus ASA (2.0 +/- 0.3) was obviously lower than that after placebo plus ASA (3.7 +/- 0.2). This reduction in lesion core by ebrotidine was accompanied by a significant increase in gastric blood flow (by 15% in corpus and 26% in antrum), by a rise in transmucosal potential difference (by 12%), and by a decrease of mucosal micro bleeding [3]. |
别名 | FI3542, 乙溴替丁 |
分子量 | 477.42 |
分子式 | C14H17BrN6O2S3 |
CAS No. | 100981-43-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (209.46 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0946 mL | 10.473 mL | 20.9459 mL | 52.3648 mL |
5 mM | 0.4189 mL | 2.0946 mL | 4.1892 mL | 10.473 mL | |
10 mM | 0.2095 mL | 1.0473 mL | 2.0946 mL | 5.2365 mL | |
20 mM | 0.1047 mL | 0.5236 mL | 1.0473 mL | 2.6182 mL | |
50 mM | 0.0419 mL | 0.2095 mL | 0.4189 mL | 1.0473 mL | |
100 mM | 0.0209 mL | 0.1047 mL | 0.2095 mL | 0.5236 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ebrotidine 100981-43-9 GPCR/G Protein Immunology/Inflammation Neuroscience Histamine Receptor FI 3542 FI-3542 FI3542 inhibit Inhibitor 乙溴替丁 inhibitor